scholarly journals Pharmacological and clinical profile of gilteritinib (Xospata® tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia

2021 ◽  
Vol 156 (1) ◽  
pp. 37-46
Author(s):  
Masamichi Mori ◽  
Kazuyuki Hidaka
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Acute Myeloid

Clinical profile and outcome of patients of acute myeloid leukemia with high hyperdiploidy

2012 ◽  
Vol 36 (3) ◽  
pp. e60-e61
Author(s):  
Sanjeev Kumar Sharma ◽  
Monica Sharma ◽  
Tulika Seth ◽  
Pravas Mishra ◽  
Mohit Chowdhry ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Clinical Profile ◽  
Acute Myeloid

scholarly journals Clinical Profile and Short Term Outcome of Adult Patients with Acute Myeloid Leukemia

2018 ◽  
Vol 35 (3) ◽  
pp. 431-436 ◽  
Author(s):  
Sherin Jacob ◽  
Sajini Elizabeth Jacob ◽  
Bettadpura Shamanna Suryanarayana ◽  
Tarun Kumar Dutta
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Adult Patients ◽  
Clinical Profile ◽  
Short Term ◽  
Term Outcome ◽  
Short Term Outcome ◽  
Acute Myeloid

scholarly journals Clinical profile of acute myeloid leukemia in North India and utility of nontransplant measures in its management

2019 ◽  
Vol 40 (5) ◽  
pp. 44
Author(s):  
Javvid Muzamil ◽  
Nadeem Shoket ◽  
TasneefBanoo Zargar ◽  
Burhan Wani ◽  
Vishal Toka ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Clinical Profile ◽  
North India ◽  
Acute Myeloid

Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia

2020 ◽  
Vol 16 (1) ◽  
pp. 18
Author(s):  
MS Namratha Udupa ◽  
KGovind Babu ◽  
MC Suresh Babu ◽  
KC Lakshmaiah ◽  
D Lokanatha ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Treatment Outcomes ◽  
Myeloid Leukemia ◽  
Clinical Profile ◽  
Acute Myeloid

scholarly journals Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study

2018 ◽  
Vol 109 (10) ◽  
pp. 3235-3244 ◽  
Author(s):  
Kensuke Usuki ◽  
Toru Sakura ◽  
Yukio Kobayashi ◽  
Toshihiro Miyamoto ◽  
Hiroatsu Iida ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Phase 1 ◽  
Japanese Patients ◽  
Clinical Profile ◽  
Open Label ◽  
Phase 1 Study ◽  
Open Label Phase ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients

Diagnostics ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 263 ◽  
Author(s):  
Sergiu Pasca ◽  
Cristina Turcas ◽  
Ancuta Jurj ◽  
Patric Teodorescu ◽  
Sabina Iluta ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hematologic Malignancy ◽  
Clinical Profile ◽  
World Health ◽  
Dismal Prognosis ◽  
Classical Statistics ◽  
Similar Phenotype ◽  
Health Organization ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by abnormal proliferation and a lack of differentiation of myeloid blasts. Considering the dismal prognosis this disease presents, several efforts have been made to better classify it and offer a tailored treatment to each subtype. This has been formally done by the World Health Organization (WHO) with the AML classification schemes from 2008 and 2016. Nonetheless, there are still mutations that are not currently included in the WHO AML classification, as in the case of some mutations that influence methylation. In this regard, the present study aimed to determine if some of the mutations that influence DNA methylation can be clustered together regarding methylation, expression, and clinical profile. Data from the TCGA LAML cohort were downloaded via cBioPortal. The analysis was performed using R 3.5.2, and the necessary packages for classical statistics, dimensionality reduction, and machine learning. We included only patients that presented mutations in DNMT3A, TET2, IDH1/2, ASXL1, WT1, and KMT2A. Afterwards, mutations that were present in too few patients were removed from the analysis, thus including a total of 57 AML patients. We observed that regarding expression, methylation, and clinical profile, patients with mutated TET2, IDH1/2, and WT1 presented a high degree of similarity, indicating the equivalence that these mutations present between themselves. Nonetheless, we did not observe this similarity between DNMT3A- and KMT2A-mutated AML. Moreover, when comparing the hypermethylating group with the hypomethylating one, we also observed important differences regarding expression, methylation, and clinical profile. In the current manuscript we offer additional arguments for the similarity of the studied hypermethylating mutations and suggest that those should be clustered together in further classifications. The hypermethylating and hypomethylating groups formed above were shown to be different from each other considering overall survival, methylation profile, expression profile, and clinical characteristics. In this manuscript, we present additional arguments for the similarity of the effect generated by TET2, IDH1/2, and WT1 mutations in AML patients. Thus, we hypothesize that hypermethylating mutations skew the AML cells to a similar phenotype with a possible sensitivity to hypermethylating agents.

Sign in / Sign up

Export Citation Format

Share Document